A Shorter Halving Time for BCR-ABL transcript Reduction Is a Novel Predictor of Molecular Response Achievement in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patients Treated with Dasatinib: Results of D-First Study
scholarly article
Author/s
Work details
Publication date:
December 6, 2014
Language:
English
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
